Introduction: Lacosamide is a noval anti-epileptic drug, which is being evaluated for the treatment of Neuropathic Pain. The role of pregabalin in neuropathic pain is already well-established. So, the scope of the study is to compare the effectiveness of lacosamide (a newer molecule), with a well-established pregabalin.

Methods: 107 patients, who met the inclusion criteria, were enrolled in the study. Patients are randomly arranged into 2 groups, each group receiving either lacosamide or pregabalin. Comparison is done among both the groups, to assess the Efficacy, and Quality of Life, using Visual Analog Scale (VAS) and SF-36 Questionnaire respectively. Patients are assessed during the first visit, and follow up is done after one month of initial treatment and subsequent reviews done in 2 months interval, up to 6 months.

Results: After analysis it was found that out of 107 patients, 54 patients were enrolled into the lacosamide treatment group and the remaining 53 into the pregabalin treatment group.Severity of pain was significantly reduced in patients treated with lacosamide, compared to that of pregabalin. Quality of life of the patients treated with lacosamide showed greater improvement compared to that of pregabalin.

Conclusion: Based on study results, it was concluded that lacosamide has greater efficacy compared to that of pregabalin. Patients treated with lacosamide had significant improvement in quality of life compared to that of pregabalin. Consequently, this study supports the use of lacosamide for neuropathic pain over pregabalin.

Keywords: Lacosamide, Pregabalin, SF-36 Questionnaire, Quality of life.

1. H, Martin. J. (2008). Harrison’s Principles of Internal medicine; pain: pathophysiology and management. 16^th ed. New York: McGraw-Hill, pp.71-76.
2. Woolf CJ, Mannion RJ. Neuropathic pain: etiology, symptoms, mechanisms and management. Lancet 1999; 353:1959–64.
3. Attal N, Fermanian C, Fermanian J, Lanteri-Minet M, Alchaar H, Bouhassira D. Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion? Pain 2008; 138:343–53.
4. Attal N, Cruccu G, Haanpää M, Hansson P, Jensen TS, Nurmikko T, Sampaio C, Sindrup S, Wiffen P; EFNS Task Force. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006; 13:1153–69.
5. Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice AS, Stacey BR, Treede RD, Turk DC, Wallace MS. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007; 132:237–51.
6. Cruccu G, Anand P, Attal N, Garcia-Larrea L, Haanpää M, Jørum E, Serra J, V Jensen TS. EFNS guidelines on neuropathic pain assessment. Eur J Neurol 2004; 11:153–62.
7. Verma, V., Singh, N. and Jaggi, A. (2014). Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms. Current Neuropharmacology, 12(1), pp.44-56.
8. Eisenberg E, Lurie Y, Braker C, et al. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology. 2001;57:505–509.(8)
9. Wymer J, Simpson J, Sen D, Bongardt S. Efficacy and Safety of Lacosamide in Diabetic Neuropathic Pain. The Clinical Journal of Pain. 2009;25(5):376-385.(9)
10. https://www.google.co.in/url?sa=t&source=web&rct=j&url=https://www.rand.org/health/surveys_tools/mos/36-item-short form.html&ved=2ahUKEwjglOa3jajcAhVMRo8KHRAZC-MQFjAKegQIAhAB&usg=AOvVaw0wd6KjwfB_Y_tB79mypHPL. [Accessed on 18 Jul 2018].
11. Rauck RL, Shaibani A, Biton V, et al. Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain. 2007; 23:150–158.
12. Stacey BR, Swift JN. Pregabalin for neuropathic pain based on recent clinical trials. Current pain and headache reports. 2006 Jun 1; 10(3):179-84.

Maneesha Dominic

Department of Pharmacy Practice, National College of Pharmacy, Kozhikode, 673602, Kerala, India